In the Victoza® arm of the LEADER trial, no overall differences in safety or efficacy were seen in patients with mild, moderate, or severe renal function compared to those with normal renal function.1
Victoza® was studied in patients with mild to severe renal impairmenta
aMild renal impairment=eGFR 60 to ≤89 mL/min/1.73m2; moderate renal impairment=eGFR 30-59 mL/min/1.73m2, severe renal impairment=eGFR <30 mL/min/1.73m2.
Nearly 40% of patients with type 2 diabetes may develop renal impairment2
There is limited experience with Victoza® in patients with end stage renal disease. There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.
Victoza® has not been found to be directly nephrotoxic in animal studies or clinical trials. There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis in Victoza®-treated patients. Some of these events were reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration.
Victoza® is not filtered by the kidneys3
In the LIRA-RENAL study, Victoza® showed no significant difference in renal function vs placebo as measured by eGFR4
Change the course of treatment with Victoza® for your patients with T2D and established CVD
eGFR=estimated glomerular filtration rate.
Davies (LIRA-RENAL)4: A 26-week, double-blind, placebo-controlled, parallel-group, randomized study in adult patients with type 2 diabetes and moderate renal impairment (eGFR 30-59 mL/min/1.73 m2). Patients were randomized to receive Victoza® 1.8 mg (n=140) or placebo (n=139) in addition to existing oral antidiabetics and/or insulin therapy. The primary endpoint was change in A1C.
- Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
- Bailey C, Day C. Diabetes therapies in renal impairment. Br J Diabetes Vasc Dis. 2012;12(4):167-171.
- Malm-Erjefält M, Bjørnsdottir I, Vanggaard J. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010;38(11):1944-1953.
- Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care. 2016;39(2):222-230.